Standard Drug Tx as Good as Stem Cell Transplant for Scleroderma?
Patients who underwent autologous stem cell transplantation (ASCT) for diffuse cutaneous systemic sclerosis (dcSSc), also known as scleroderma, did no better than others receiving conventional treatment, researchers found. In an analysis of systemic sclerosis patients enrolled in an Australian cohort study, those who would have been eligible for ASCT in either of two clinical trials […]
Clinical Challenges: Test Your Knowledge on Recent Advances in DLBCL
Knowledge about the biology of diffuse large B-cell lymphoma (DLBCL) and the number of treatments approved for the disease continues to grow. This three-question quiz will test one aspect from each article in MedPage Today‘s Clinical Challenges series on DLBCL that covered the following: use of bispecific antibodies versus CAR T-cell therapy in the relapsed/refractory […]
Clinical Challenges: Secondary CNS Relapse in Diffuse Large B-Cell Lymphoma
Central nervous system (CNS) relapse occurs in roughly one in 20 patients with diffuse large B-cell lymphoma (DLBCL), but in some disease subtypes that risk increases substantially. “In certain subsets of patients, the risk is quite low, but in others it can be quite high so it is better to focus on the high-risk groups,” […]
Clinical Challenges: Using Pola-R-CHP for Diffuse Large B-Cell Lymphoma
Earlier this year, the FDA approved a new frontline option for patients with diffuse large B-cell lymphoma (DLBCL): the antibody-drug conjugate polatuzumab vedotin (Polivy) in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (pola-R-CHP). Combination chemotherapy involving rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) — and before that, CHOP alone — has been the established option […]
Pre-Existing Depression, Anxiety Tied to Worse DLBCL Prognosis
Patients with diffuse large B-cell lymphoma (DLBCL) who also had pre-existing depression, anxiety, or both had a worse prognosis than those without these pre-existing mental health conditions, according to results from a population-based study. Among over 13,000 patients at a median follow-up of 2 years, the 5-year overall survival (OS) rate was 27% for patients […]
Lymphoma cell metabolism may provide new cancer target
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell’s Ithaca campus. The researchers, whose study was published Dec. 13 in Blood Cancer Discovery, showed […]